---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005294"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2026-08-06T12:00:37+00:00"
generated_at: "2026-08-06T12:06:11.553741+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026

## Summary
- Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.
- Cash, equivalents and investments $30.4M at June 30, 2026, down from $77.8M at Dec 31, 2025; expects funding through Q4 2026.
- Received $25M upfront from Amoytop for Greater China license of pevifoscorvir sodium; $3M milestone from ALG-170675 IND approval expected Q3 2026.
- Phase 2 B-SUPREME study of pevifoscorvir sodium fully enrolled (245 participants); topline data expected late Q3 2027.
- R&D expenses rose to $24.1M from $14.0M due to Phase 2 trial costs; G&A flat at $5.6M.

## SEC filing metadata
- accession: 0001171843-26-005294
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2026-08-06T12:00:37+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/0001171843-26-005294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/f8k_080526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005294
- JSON: https://secwatch.observer/filing/0001171843-26-005294.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.